Orlando, FL (PRWEB) May 09, 2012
The Pradaxa Resource Center, a patient advocacy group, is alerting patients taking the atrial fibrillation drug Pradaxa that recent information has related the drug to serious or fatal internal bleeding, and several victims have already filed lawsuits for injury or death.
If you have questions about an internal bleeding episode after taking Pradaxa, contact the Pradaxa Resource Center for more information.
Pradaxa was released in October, 2010 as a safe and effective anticoagulant for those dealing with atrial fibrillation. However, in the short time since its release, it has been the subject of an FDA warning, journal studies and injury lawsuits.
On December 7, 2011 the FDA announced that it was launching an investigation into the safety of Pradaxa after receiving higher than normal amounts of adverse reports of injury or death in patients.
Last November, Reuters reported that German drug maker Boehringer Ingelheim, who makes Pradaxa, had admitted receiving more than 260 confirmed reports of death from internal bleeding among Pradaxa users since launching the drug worldwide in 2008.
Although all anticoagulants typically carry a risk of internal bleeding, most have a reversal agent available to doctors in emergency. A March 6, 2012 report by the Journal of Neurosurgery detailed a specific case and complaints by doctors that once Pradaxa causes internal bleeding in a patient, there is very little they can do to stop it.
Many patients affected by internal bleeding after taking the drug have now contacted the Pradaxa Resource Center to inquire about their legal options based on the failure of Boehringer Ingelheim to warn of the risks.
Last month, a wrongful death lawsuit was filed against the manufacturer on behalf of a Tennessee woman who allegedly bled to death from Pradaxa side effects. Filed on April 3, 2012 by Marlene Wright on behalf of the Estate of Gertrude Eubanks, the suit alleges Eubanks died from internal bleeding on April 4, 2011, just days after she started using the drug.
The case is Marlene Wright et al v. Boehringer Ingelheim Pharmaceuticals, Case Number: 2:2012cv02262 (Western District Court of Tennessee)
Legal experts with the Pradaxa Resource Center fear that, due to the amount of people prescribed the drug in recent years, thousands may seek legal help for a serious injury or death.